Table 5 Relation between demographic, clinical, and biochemical findings and CMV and/or EBV as detected in serum by qualitative PCR assay in leukemic patients

Age

0.61

 ≤6 years (n = 23)

7 (30.4%)

5 (21.7%)

11 (47.8%)

 >6 years (n = 27)

12 (44.4%)

4 (14.8%)

11 (40.7%)

Sex

0.53

 Male (n = 26)

11 (42.3%)

3 (11.5%)

12 (46.2%)

 Female (n = 24)

8 (33.3%)

6 (25%)

10 (41.7%)

Mucositis

0.07

 Yes (n = 22)

7 (31.8%)

7 (31.8%)

8 (36.4%)

 No (n = 28)

12 (42.9%)

2 (7.1%)

14 (50.0%)

Organomegaly

0.72

 Yes (n = 35)

14 (40.0%)

7 (20.0%)

14 (40.0%)

 No (n = 15)

5 (33.3%)

2 (13.3%)

8 (53.4%)

DFN (days)

0.75

 <26.5 (n = 25)

8 (32%)

5 (20%)

12 (48%)

 >26.5 (n = 25)

11 (44%)

4 (16%)

10 (40%)

ANC (×10⁹/L)

0.07

 <0.13 (n = 25)

13 (52%)

2 (8%)

10 (40%)

 ≥0.13 (n = 25)

6 (24%)

7 (28%)

12 (48%)

Plt count (×10⁹/L)

0.27

 <39.5 (n = 25)

7 (28%)

4 (16%)

14 (56%)

 ≥39.5 (n = 25)

12 (48%)

5 (20%)

8 (32%)

Hb (gm/dL)

0.65

 <7.4 (n = 25)

10 (40%)

3 (12%)

12 (48%)

 ≥7.4 (n = 25)

9 (36%)

6 (24%)

10 (40%)

AMC(×10⁹/L)

0.43

 <0.11 (n = 25)

9 (36%)

3 (12%)

13 (52%)

 ≥0.11 (n = 25)

10 (40%)

6 (24%)

9 (36%)

TLC(cell/mm³)

0.57

 <11950 (n = 25)

11 (44%)

5 (20%)

9 (36%)

 ≥11950 (n = 25)

8 (32%)

4 (16%)

13 (52%)

ALC(×10⁹/L)

0.93

 <1.2 (n = 24)

10 (41.7%)

4 (16.7%)

10 (41.7%)

 ≥1.2 (n = 26)

9 (34.6%)

5 (19.2%)

12 (46.2%)